Viracta Therapeutics (NASDAQ:VIRX – Free Report) had its price objective trimmed by Royal Bank of Canada from $6.00 to $4.00 in a report issued on Thursday, Benzinga reports. The firm currently has an outperform rating on the stock.
Separately, Oppenheimer reduced their price objective on shares of Viracta Therapeutics from $13.00 to $11.00 and set an outperform rating for the company in a research report on Thursday, May 23rd.
Get Our Latest Stock Report on Viracta Therapeutics
Viracta Therapeutics Price Performance
About Viracta Therapeutics
Viracta Therapeutics, Inc, a clinical-stage precision oncology company, focuses on the treatment and prevention of virus-associated cancers that impact patients worldwide. Its lead product candidate is Nana-val, an all-oral combination therapy of its proprietary investigational drug, nanatinostat, and the antiviral agent valganciclovir.
Featured Stories
- Five stocks we like better than Viracta Therapeutics
- How to Invest in the FAANG Stocks
- This Small Cap Wealth Management Stock Could Provide Big Returns
- How to Buy Cheap Stocks Step by Step
- Bumble’s Valuation Hits an All-Time Low, Can Its Fortunes Change?
- How Investors Can Identify and Successfully Trade Gap-Down Stocks
- MarketBeat Week in Review – 8/12 – 8/16
Receive News & Ratings for Viracta Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Viracta Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.